Company news

Share this article:
Pfizer announced that it has entered into a $15 million dollar collaboration with the University of Pennsylvania School of Medicine. The partnership will include collaborations between Pfizer and the university in the areas of scientific research, clinical development and clinical care and policy. Under the terms of the agreement, Pfizer will pay Penn $15 million over a three-year period, during which time scientists from Pfizer and Penn's School of Medicine will work together on several projects of mutual interest including basic and translational research addressing several therapeutic areas. Project proposals will be solicited and reviewed by a committee with representation from both parties. The initial emphasis of the collaboration will focus on the neurosciences and oncology, but may expand to other areas, Pfizer said in a statement.

Omnicom's digital and CRM-intensive STAR Marketing network launched a healthcare offering. STAR Healthcare will offer “integrated, personalized” direct to patient programs under the guidance of managers to be announced in two unique positions: those of “patient advocate” and “client champion.”

Ketchum launched Well Connected, a “cross-practice health and wellness specialty” aimed at leveraging the shop's expertise in health and wellness, influencer relationships and proprietary research in food and nutrition, healthcare and brand. In addition to research, the practice also offers clients a partnership with the National Senior Games Association and supermarket and branding expert Phil Lempert.  
Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.